Once all of the one-time charges were washed out of the numbers, Pfizer recorded adjusted income of $4.2 billion, an increase of 5% compared with $4.0 billion in the year-ago quarter, and EPS of $.62, an increase of 7% compared with $.58 in the year-ago quarter. The firm hit these numbers despite a drop in sales of its Zyrtec and Camptosar products.
Viagra and Lipitor continued to do well, a bit of a commentary on life in the US in 2008.
Perhaps most important, Pfizer upped its forecasts. The pharma firm raised the lower end of its guidance range for full-year 2008 revenues to $48.0 to $49.0 billion from $47.0 to $49.0 billion.
All in all, a pretty outstanding set of numbers
Douglas A. McIntyre